More NewsRead More
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
July 27, 2015
Nymox Announces Appointment of Erik Danielsen as CFO
July 13, 2015
Recent Highlights from the Healthcare Sector: Complementary Research on BioMarin, Seattle Genetics, Globus Medical, Nymox and Progenics
May 11, 2015
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here